Regulatory Roundup: Week of October 15, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup: Week of October 15, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has opened public consultation on the revised CHMP Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Acute Heart Failure (CHMP/EWP/2986/03 Rev.1).

EMA also released its guideline on medicinal products for the treatment of schizophrenia on Oct. 9, 2012. The guideline describes requirements for the development of medicinal products with regard to study design, patient population, and outcome measures and goes into effect on Apr. 1, 2013.

FDA has collected generic drug information and made it available on their website for industry. The website include guidance document updates, recent meeting minutes, reports, and other relevant information.

Recent guidance documents published by FDA include E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Questions and Answers (R1) (October 2012). A comprehensive list of FDA guidance documents can be found on and well as a list of withdrawn guidance documents.

The Orange Book, the Approved Drug Products with Therapeutic Equivalence Evaluations, has been updated with additions and deletions of prescription and OTC products.

The International Conference on Harmonization has released the final meeting report from the latest Global Cooperation Group meeting held in Fukuoka, Japan on June 5, 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here